TOP TEN perturbations for 40019_at (Homo sapiens)

Organism: Homo sapiens
Gene: 40019_at
Selected probe(set): 211742_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 40019_at (211742_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-5.5413485
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-4.2854166
Number of Samples:8 / 2
Experimental expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

glioma study 16 (LN-18) / normal astrocyte sample

Relative Expression (log2-ratio):4.233844
Number of Samples:2 / 3
Experimental glioma study 16 (LN-18)
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

expO ovary cancer study 1 (endometrioid carcinoma; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-4.230139
Number of Samples:3 / 2
Experimental expO ovary cancer study 1 (endometrioid carcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

T-cell activation study 4 / normal resting T-cell sample

Relative Expression (log2-ratio):-4.11738
Number of Samples:2 / 2
Experimental T-cell activation study 4
T-cell samples antiCD3 activated for 30hrs.
Control normal resting T-cell sample
T cells resting for 30h.

renal cell carcinoma study 4 / normal kidney tissue (fetal)

Relative Expression (log2-ratio):4.116392
Number of Samples:26 / 2
Experimental renal cell carcinoma study 4
Tumor tissue samples from the kidney of patients with renal cell carcinoma (RCC).
Control normal kidney tissue (fetal)
Normal fetal kidney tissue samples.

T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample

Relative Expression (log2-ratio):-4.068307
Number of Samples:2 / 2
Experimental T-cell activation study 3
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs.
Control resting CD4 T-lymphocyte (crude fraction) sample
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction.

expO ovary cancer study 1 (serous surface papillary carcinoma; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)

Relative Expression (log2-ratio):3.8751717
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (serous surface papillary carcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous surface papillary carcinoma of the ovary.
Control expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.

TNF-ɑ; IL-1b; IL-6; PGE2 study 1 / control antibody treated immature dendritic cell sample

Relative Expression (log2-ratio):-3.7716646
Number of Samples:4 / 5
Experimental TNF-ɑ; IL-1b; IL-6; PGE2 study 1
Immature dendritic cells (DCs) treated with inflammatory cytokine cocktail (10 ng/ml IL-1b, 1,000 U/ml IL-6, 10 ng/ml TNF-ɑ, 1μg/ml prostaglandin E2) for 24 h.
Control control antibody treated immature dendritic cell sample
Immature dendritic cells (DCs) treated with isotype control antibody (10 - 20μg/ml mouse IgG1 isotype) for 24 h.

VTX-2337 study 1 / untreated monocyte sample

Relative Expression (log2-ratio):-3.7648706
Number of Samples:3 / 3
Experimental VTX-2337 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control untreated monocyte sample
Peripheral blood monocytes isolated from healthy donors.